Cytological features of myxoid adrenocortical adenoma with a pseudoglandular component: A case report with differential diagnostic considerations

Ishida, Mitsuaki; Yoshida, Keiko; Miyamoto, Keiko; Iwai, Muneo; Miyahira, Yoshimitsu; Kushima, Ryoji; Okabe, Hidetoshi

doi:10.1002/dc.20854

Cited by 5 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, four out of six myxoid ACAs reported in a series by Brown et al [49] were large (≥ 6 cm), showed focal capsular invasion and a mitotic activity of ≥ 1/10 HPFs in the absence of recurrence or metastatic disease after a mean follow-up period of 12 years. It should be stressed that 9 out of 17 myxoid ACAs were relatively large (≥ 6 cm), a feature further challenging the prediction of a benign clinical course [49, 50, 54–57]. …”

Section: Part II Adrenocortical Carcinoma Variantsmentioning

confidence: 99%

Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants

Krijger

Papathomas

2011

Virchows Arch

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare, heterogeneous malignancy with a poor prognosis. According to WHO classification 2004, ACC variants include oncocytic ACCs, myxoid ACCs and ACCs with sarcomatous areas. Herein, we provide a comprehensive review of these rare subtypes of adrenocortical malignancy and emphasize their clinicopathological features with the aim of elucidating aspects of diagnostic categorization, differential diagnostics and biological behavior. The issue of current terminology, applied to biphasic tumors with pleomorphic, sarcomatous or sarcomatoid elements arising in adrenal cortex, is also discussed. We additionally present emerging evidence concerning the adrenal cortical tumorigenesis and the putative adenoma–carcinoma sequence as well.

show abstract

Section: Part II Adrenocortical Carcinoma Variantsmentioning

confidence: 99%

Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants

Krijger

Papathomas

2011

Virchows Arch

View full text Add to dashboard Cite

show abstract

“…To date, including adenomas and carcinomas, a total of 41 cases (21 carcinomas, 3 borderline malignancies, and 17 adenomas) have been reported in the English literature. [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] Because the presence of myxoid changes in adrenocortical neoplasms often raises the possibility of malignancy, we aimed to explore the clinicopathologic and molecular biologic features of myxoid adrenocortical neoplasms in this study.…”

Section: Detection Of Egfr Protein Expression May Be Useful In the DImentioning

confidence: 99%

Myxoid Adrenocortical Neoplasms

Zhang

Sun

Liang

et al. 2011

American Journal of Clinical Pathology

View full text Add to dashboard Cite

The histopathologic features of 10 myxoid adrenocortical neoplasms were analyzed, and epidermal growth factor receptor (EGFR) expression, EGFR gene copy number, and EGFR gene mutations in the 10 tumors were detected by using immunohistochemical analysis, fluorescence in situ hybridization, and the Scorpion Amplification Refractory Mutation System (DxS, Manchester, England), respectively. Histologically, all 10 tumors varied in their myxoid composition, ranging from 20% to 95%. EGFR protein overexpression was more frequent in myxoid adrenocortical carcinomas (3/4) than in myxoid adrenocortical adenomas (0/6). However, EGFR mutations and EGFR amplification were rare. All patients with adenomas survived for the follow-up period with no recurrence of their tumors or evidence of metastatic disease; 3 patients with carcinoma died of the disease, and 1 is alive with disease. Myxoid changes in adrenocortical neoplasms can be present in adenomas and carcinomas. Detection of EGFR protein expression may be useful in the differential diagnosis between adrenocortical adenomas and adrenocortical carcinomas.

show abstract

“…Following the original report by Tang and coworkers (26), 32 functioning or non-functioning myxoid ACT have been described, including 18 adenomas, 13 carcinomas and one borderline case (3,4,6,7,9,10,(13)(14)(15)(16)(17)19,23,25,30). Myxoid changes may also be present in pediatric ACT, judging from the images (Fig.…”

Section: Introductionmentioning

confidence: 99%

Adrenocortical Tumors With Myxoid Features: A Distinct Morphologic and Phenotypical Variant Exhibiting Malignant Behavior

Papotti

Volante

Duregon

et al. 2010

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Myxoid changes have been rarely reported both in adrenocortical adenomas and carcinomas. The recent observation by our group of an adrenal myxoid tumor with morphologically borderline features but aggressive clinical behavior prompted us to review a series of 196 adrenocortical lesions, comprising 122 carcinomas and 74 adenomas, to define the morphological, phenotypical and clinical characteristics of adrenocortical tumors with myxoid features. Fourteen cases, including 12 carcinomas and 2 borderline tumors, formed the basis of this report, and were characterized by a variably abundant myxoid component (from 5% to 90% of tumor) and two distinct cellular growth patterns: the first (10 cases), mostly associated with a predominant myxoid stromal component, was made of small cells with mild atypia arranged in cords and microcysts; the second (4 cases) was characterized by focal myxoid changes in tumors otherwise similar to conventional adrenocortical carcinoma, with large atypical cells having an eosinophilic cytoplasm and a diffuse or nodular architecture. The above mentioned patters were absent in all adenomas reviewed. A peculiar reactivity to neurofilaments was seen, mostly associated to the presence of predominant rather that focal myxoid stromal changes, as well as in 40% of conventional adrenocortical carcinomas, thus representing an undescribed potential pitfall in the differential diagnosis of adrenal lesions. Myxoid adrenocortical tumors probably represent a rare but histologically and phenotipically distinct entity and, although rare cases of benign lesions are on record, they seem to be generally associated to morphological and clinical features of malignancy.

show abstract

Cytological features of myxoid adrenocortical adenoma with a pseudoglandular component: A case report with differential diagnostic considerations

Cited by 5 publications

References 7 publications

Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants

Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants

Myxoid Adrenocortical Neoplasms

Adrenocortical Tumors With Myxoid Features: A Distinct Morphologic and Phenotypical Variant Exhibiting Malignant Behavior

Contact Info

Product

Resources

About